GammaCan Participates in 2006 Vitiligo Support National Conference; Company Joins Community in Exploring Treatment Alternatives
26 July 2006 - 9:30PM
Business Wire
GammaCan International (OTC BB:GCAN) today announced that Patrick
Schnegelsberg, CEO, participated at and presented at the 2006
Vitiligo Support National Conference held at the Hilton Universal
City near Los Angeles in California from July 14th through the
16th. The conference featured individuals with vitiligo, physicians
and other experts in vitiligo treatments, pathology, new research,
autoimmune diseases and more. "GammaCan is aiming at becoming
actively involved and work with the vitiligo community. In
addition, we are exploring if we could be in a position to provide
needed options to the vitiligo community while at the same time
assisting patients suffering from metastatic malignant melanoma.
VitiGam, an innovative anti-cancer product designed to treat Stage
III and IV melanoma, may play a role here," stated Patrick
Schnegelsberg. About VitiGam: VitiGam is GammaCan's second
generation intravenous IgG-based product and a first-in-class
anti-cancer immunotherapy. GammaCan plans on having VitiGam enter
phase I/II testing under a US IND in the near future after recently
holding a pre-IND meeting with the FDA. VitiGam is being designed
to target metastatic melanoma patients with Stage III and IV
melanoma. VitiGam is an IgG product that is different from standard
IgGs: It is manufactured from the plasma of donors with vitiligo, a
benign autoimmune skin condition affecting up to 2% of the general
population. GammaCan scientists have shown that this "enriched"
vitiligo IgG (VitiGam) contains potent anti-melanoma activity in
both in vitro and mouse xenograft melanoma models. Thus, GammaCan
expects VitiGam to provide (1) anti-melanoma activity directed
specifically against malignant melanoma cells and (2) non-specific
anti-cancer activity - as is the case with IgG in general. About
Vitiligo Support International: Vitiligo Support International, the
largest vitiligo organization in the world, is a global community
organization committed to supporting those affected by vitiligo,
raising awareness, promoting research, and discussing effective
treatments until a cure is found. Their website is at
www.VitiligoSupport.org About GammaCan: GammaCan is focusing on the
commercialization of an innovative anti-cancer immunotherapy to
treat metastatic cancer. GammaCan's platform is based on IVIg, a
safe, relatively non-toxic human plasma-based product, currently
used to treat a variety of immune deficiencies and autoimmune
diseases. IVIg works by strengthening the patient's immune system.
Many experts currently view immunotherapy as a future alternative
to today's standard chemotherapy. GammaCan is developing VitiGam,
its second generation program. VitiGam is an IVIg derived from the
plasma of vitiligo donors and is being developed to treat malignant
melanoma. GammaCan owns, and has applied for US patent protection
covering the use of IVIg and vitiligo-derived IVIg (VitiGam). For
more information about GammaCan visit www.GammaCan.com or call the
company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616
or toll free 1-866-308-0396 (from North America). Safe Harbor
Statement: Statements in this document that are not purely
historical are forward-looking statements. Forward-looking
statements in this release include statements regarding the
commercialization of an anti-cancer immunotherapy and the Company
developing the boosting of cancer patients' immune systems with
IVIg into an effective treatment. Actual outcomes and the Company's
actual results could differ materially from those in such
forward-looking statements. Factors that could cause actual results
to differ materially include risks and uncertainties such as the
inability to finance the planned development of the technology,
unforeseen technical difficulties in developing the technology, the
inability to obtain regulatory approval for human use, competitors'
therapies proving more effective, cheaper or otherwise preferable
for consumers, inability to market the product we produce, among
other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further
risk factors see the risk factors associated with other early state
medical research and development companies filed with the SEC on
Edgar.
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2023 to Jul 2024